NRAS and neoplasm: Furthermore, we show that finding an additional NRAS mutation in a tumor sample following BRAF inhibitor treatment could indicate the presence of a double mutated subpopulation that is not necessarily sensitive to MEK inhibition or ERK inhibition, rendering the MEK inhibitor therapy in all such cases suboptimal.